FASLG and metabolic dysfunction-associated steatohepatitis: Finally, we confirmed that treatment with anti-FasL Ab during the resolution phase partially prevented the regression from NASH (Fig. 8i–o) and decreased apoptotic HSCs (Fig. 8p).